View in EDS

Increasing Alcohol Pharmacotherapy Prescribing Rates in Australia: Implementing Evidence‐Based Treatment for Alcohol Use Disorder.

Saved in:
Bibliographic Details
Title: Increasing Alcohol Pharmacotherapy Prescribing Rates in Australia: Implementing Evidence‐Based Treatment for Alcohol Use Disorder.
Authors: Naren, Thileepan (AUTHOR), Membrey, Dean (AUTHOR), MacCartney, Paul (AUTHOR), Kuntsche, Sandra (AUTHOR), Cook, Megan (AUTHOR), Jiang, Heng (AUTHOR), Kuntsche, Emmanuel (AUTHOR)
Source: Drug & Alcohol Review. Nov2025, Vol. 44 Issue 7, p2057-2060. 4p.
Subjects: Alcoholism, Baclofen, Cirrhosis of the liver, Temperance, Drug therapy, Naltrexone, Evidence-based medicine
Geographic Terms: Australia
Abstract: The article focuses on the case of a 32-year-old woman with a history of severe alcohol use disorder (AUD) and Child's Pugh C cirrhosis, highlighting the significant health impacts of alcohol consumption and the potential benefits of alcohol pharmacotherapy. Despite previous treatment attempts, including detoxification and psychosocial support, the patient showed limited improvement until she was prescribed baclofen, which led to a notable reduction in drinking and improved overall health. The commentary emphasizes the underutilization of pharmacotherapy options like naltrexone and acamprosate in Australia, despite their proven effectiveness, and calls for a shift in treatment paradigms to better address the needs of individuals with AUD. The authors advocate for increased access to evidence-based pharmacotherapies to reduce the personal and societal costs associated with alcohol-related harm. [Extracted from the article]
Copyright of Drug & Alcohol Review is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:The article focuses on the case of a 32-year-old woman with a history of severe alcohol use disorder (AUD) and Child's Pugh C cirrhosis, highlighting the significant health impacts of alcohol consumption and the potential benefits of alcohol pharmacotherapy. Despite previous treatment attempts, including detoxification and psychosocial support, the patient showed limited improvement until she was prescribed baclofen, which led to a notable reduction in drinking and improved overall health. The commentary emphasizes the underutilization of pharmacotherapy options like naltrexone and acamprosate in Australia, despite their proven effectiveness, and calls for a shift in treatment paradigms to better address the needs of individuals with AUD. The authors advocate for increased access to evidence-based pharmacotherapies to reduce the personal and societal costs associated with alcohol-related harm. [Extracted from the article]
ISSN:09595236
DOI:10.1111/dar.70046